Medicine and Health Sciences Commons^™

Dropout From Exercise Trials Among Cancer Survivors—An Individual Patient Data Meta-Analysis From The Polaris Study, Benedikte Western, Andreas Ivarsson, Ingvild Vistad, Ingrid Demmelmaier, Neil K. Aaronson, Gillian Radcliffe, Marc Van Beurden, Martin Bohus, Kerry S. Courneya, Amanda J. Daley, Daniel A. Galvão, Rachel Garrod, Martine M. Goedendorp, Kathleen A. Griffith, Wim H. Van Harten, Sandi C. Hayes, Fernando Herrero-Roman, Anouk E. Hiensch, Melinda L. Irwin, Erica James, Marlou-Floor Kenkhuis, Marie J. Kersten, Hans Knoop, Alejandro Lucia, Anne M. May, Alex Mcconnachie, Willem Van Mechelen, Nanette Mutrie, Robert U. Newton, Frans Nollet, Hester S. Oldenburg, Ron Plotnikoff, Martina E. Schmidt, Katie H. Schmitz, Karl-Heinz Schulz, Camille E. Short, Gabe S. Sonke, Karen Steindorf, Martijn M. Stuiver, Dennis R. Taaffe, Lene Thorsen, Miranda J. Velthuis, Jennifer Wenzel, Kerri M. Winters-Stone, Joachim Wiskemann, Sveinung Berntsen, Laurien M. Buffart

Research outputs 2022 to 2026

Introduction: The number of randomized controlled trials (RCTs) investigating the effects of exercise among cancer survivors has increased in recent years; however, participants dropping out of the trials are rarely described. The objective of the present study was to assess which combinations of participant and exercise program characteristics were associated with dropout from the exercise arms of RCTs among cancer survivors. Methods: This study used data collected in the Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS) study, an international database of RCTs investigating the effects of exercise among cancer survivors. Thirty-four exercise trials, with a total of 2467 patients …

Multimodal Exercise In Older Patients With Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy: A Case Series Examining Feasibility And Preliminary Efficacy, Hao Luo, Daniel A. Galvão, Robert U. Newton, Colin I. Tang, Nigel Spry, Dennis R. Taaffe

Research outputs 2022 to 2026

Purpose. Exercise is emerging as an adjunct therapy to cancer treatment; however, its role in older patients with advanced pancreatic cancer undergoing first-line chemotherapy is unclear. The aim of this study was to primarily provide evidence on feasibility with an exploratory examination of the initial efficacy of exercise in this clinical setting.

Materials and Methods. Six patients aged 60–75 years with de novo or recurrent advanced pancreatic cancer undergoing first-line chemotherapy consented to participate in twice-weekly exercise that included resistance and aerobic training and boxing-related activities for up to 12 weeks. Patients were monitored for attendance, adherence, and …

Changes In Body Composition In Patients With Malignant Pleural Mesothelioma And The Relationship With Activity Levels And Dietary Intake, Emily Jeffery, Y. C. Gary Lee, Robert U. Newton, Philippa Lyons-Wall, Joanne Mcveigh, Deirdre B. Fitzgerald, Leon Straker, Carolyn J. Peddle-Mcintyre

Research outputs 2022 to 2026

Background:

Skeletal muscle loss is common in advanced cancer and is associated with negative outcomes. In malignant pleural mesothelioma (MPM), no study has reported body composition changes or factors associated with these changes. This study aimed to describe changes in body composition over time and its relationship with activity levels, dietary intake and survival.

Methods:

The study was a secondary analysis of data collected from a longitudinal observational study of patients with MPM. Participants completed 3-month assessments for up to 18 months. Participants with two dual-energy x-ray absorptiometry (DXA) scans were included. Changes in appendicular skeletal muscle mass (ASM) and …

Exercise In Advanced Prostate Cancer Elevates Myokine Levels And Suppresses In-Vitro Cell Growth, Jin Soo Kim, Dennis R. Taaffe, Daniel A. Galvão, Nicolas H. Hart, Elin Gray, Charles J. Ryan, Stacey A. Kenfield, Fred Saad, Robert U. Newton

Research outputs 2022 to 2026

Background:

Altering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect.

Methods:

Twenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition …